• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

lewis.au@unimelb.edu.au

Credentials


Position
Honorary Conjoint Fellow
The Sir Peter MacCallum Department of Oncology

Dr Lewis Au

Honorary Conjoint Fellow
The Sir Peter MacCallum Department of Oncology

61 Scholarly works
0 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Thrombotic Microangiopathy in Patients Treated with 177Lu-PSMA Combination Therapies.
    DOI: 10.2967/jnumed.126.272085
  • 2026

    Journal article

    A phase 1/2 study to assess peptidomimetic carbonic anhydrase IX imaging and therapy with [68Ga]Ga-DPI-4452 and [177Lu]Lu-DPI-4452 in patients with advanced clear cell renal cell carcinoma and other solid tumors.
    DOI: 10.1200/JCO.2026.44.7_suppl.TPS569
  • 2026

    Journal article

    Retraction note: Antibodies against endogenous retroviruses promote lung cancer immunotherapy (Nature, (2023), 616, 7957, (563-573), 10.1038/s41586-023-05771-9)
    DOI: 10.1038/s41586-026-10104-7
  • 2026

    Journal article

    Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials
    DOI: 10.1016/j.eururo.2026.03.024
  • 2026

    Journal article

    Nuclear Imaging in Renal Cell Carcinoma: Current Evidence and Clinical Applications
    DOI: 10.3390/cancers18020195
  • 2025

    Journal article

    Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial
    DOI: 10.1016/S1470-2045(25)00559-5
  • 2025

    Journal article

    Neoadjuvant Pembrolizumab and Stereotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma (NAPSTER): A Phase II Randomised Clinical Trial
    DOI: 10.1016/j.ijrobp.2025.06.1178
Lewis Au

RECENT SCHOLARLY WORKS

  • 2025

    Conference Proceedings

    2386P A phase I/II trial of combined Radium-223 and Lutetium-177 PSMA-I&T in patients with metastatic castration-resistant prostate cancer (mCRPC): First analysis of the AlphaBet trial
    DOI: 10.1016/j.annonc.2025.08.3002
  • 2025

    Journal article

    First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study
    DOI: 10.1016/S1470-2045(25)00332-8
  • 2025

    Journal article

    Therapy-Related Myeloid Neoplasms After [177Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series
    DOI: 10.2967/jnumed.124.268640

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Campus locations  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia

facebookIconlinkedinIconinstagramIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224